Irish journal of medical science · 2025
MiR-144-3p participates in the regulation of gestational diabetes mellitus by targeting FOXO1.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Meiyi, Sun Shaomeng, Ma Lei, Bian Li, Zhao Biao, Zeng Haiyong
Аннотация
BACKGROUND: The pivotal role of microRNAs (miRNAs) in the pathogenesis of gestational diabetes mellitus (GDM) have been increasingly highlighted in recent studies.
AIMS: To investigate miR-144-3p expression in patients with GDM and its potential mechanisms in GDM.
METHODS: According to the inclusion criteria, 98 pregnant women with GDM and 98 normal pregnant women were statistically selected. The levels of miR-144-3p were determined by RT-qPCR. The ROC curve was used to evaluate the diagnostic value of miR-144-3p for GDM. Pearson analysis was used to analyze the correlation. HRT-8/SVneo cells were induced by high glucose in vitro to mimic the high glucose environment of GDM. On this basis, the cell models of miR-144-3p overexpression and knockdown were established to investigate the potential mechanism of miR-144-3p in GDM.
RESULTS: The level of miR-144-3p in GDM group was markedly higher than that in normal pregnant women. In terms of predicting GDM, miR-144-3p demonstrated high accuracy. MiR-144-3p was positively linked to blood glucose markers in GDM. Further investigation has confirmed that miR-144-3p harbors a binding site for FOXO1 and can directly modulate its expression. Moreover, miR-144-3p targeted FOXO1 to affect the proliferation of trophoblast cells.
CONCLUSION: The expression of miR-144-3p is elevated in pregnant women with GDM. MiR-144-3p may be involved in the regulation of GDM by targeting FOXO1.
AIMS: To investigate miR-144-3p expression in patients with GDM and its potential mechanisms in GDM.
METHODS: According to the inclusion criteria, 98 pregnant women with GDM and 98 normal pregnant women were statistically selected. The levels of miR-144-3p were determined by RT-qPCR. The ROC curve was used to evaluate the diagnostic value of miR-144-3p for GDM. Pearson analysis was used to analyze the correlation. HRT-8/SVneo cells were induced by high glucose in vitro to mimic the high glucose environment of GDM. On this basis, the cell models of miR-144-3p overexpression and knockdown were established to investigate the potential mechanism of miR-144-3p in GDM.
RESULTS: The level of miR-144-3p in GDM group was markedly higher than that in normal pregnant women. In terms of predicting GDM, miR-144-3p demonstrated high accuracy. MiR-144-3p was positively linked to blood glucose markers in GDM. Further investigation has confirmed that miR-144-3p harbors a binding site for FOXO1 and can directly modulate its expression. Moreover, miR-144-3p targeted FOXO1 to affect the proliferation of trophoblast cells.
CONCLUSION: The expression of miR-144-3p is elevated in pregnant women with GDM. MiR-144-3p may be involved in the regulation of GDM by targeting FOXO1.